Scaling up treatment programmes and increasing access to affordable quality drugs, including second- and third-line treatment, is of paramount importance.
Oluline on tõhustada raviprogramme ning parandada soodsa hinnaga kvaliteetravimite, sealhulgas teise ja kolmanda grupi ravimeetodite kättesaadavust.